Featured Research

from universities, journals, and other organizations

Adjuvant therapy perhaps not necessary for older breast cancer patients, study suggests

Date:
August 31, 2011
Source:
Journal of the National Cancer Institute
Summary:
Breast cancer patients over the age of 60 with early-stage, hormone-responsive small tumors who forgo adjuvant endocrine, also called hormonal therapy, are not at an increased risk of mortality compared to women of the same age without breast cancer, according to a new study.

Breast cancer patients over the age of 60 with early-stage, hormone-responsive small tumors who forego adjuvant endocrine, also called hormonal therapy, are not at an increased risk of mortality compared to women of the same age without breast cancer, according to a study published Aug. 31 in the Journal of the National Cancer Institute.

The use of hormonal therapy has increased in breast cancer patients overall, and the 2009 St. Gallen International Breast Cancer Conference recommended hormonal therapy for almost all patients with hormone-responsive disease. But previous studies have not identified patient subgroups that might not need adjuvant therapy or those who without the therapy would have the same longevity as women in the general population.

To identify patient sub-groups who may or may not benefit from adjuvant hormone therapy, Peer Christiansen, M.D., of the Aarhus University Hospital in Denmark and colleagues, looked at a population-based cohort of untreated breast cancer patients in Denmark. They identified 3197 patients with node-negative breast cancer from the Danish Breast Cancer Cooperative Group, between the ages of 35 and 74. The patients were not given adjuvant hormone therapy or chemotherapy.

The researchers obtained data on the mortality rate of the general Danish female population from Statistics Denmark. The researchers then estimated the relative risk of death among women in the study compared to the general population by calculating the standardized mortality ratios, or the ratio of the observed number of deaths among patients in the cohort compared to the expected number of deaths in the general population.

The researchers found that the excess mortality rate in the patient population was highest for patients aged between 35 and 39 years and lowest for those aged 60-64 years. The relative mortality of patients compared to the general population was also greater for patients with tumors larger than 10 millimeters. The researchers write: "Age less than 60 years at diagnosis and tumor size greater than 10 millimeters were independently associated with a worse prognosis."

However, they also identified a group of low-risk patients aged 60 or older with mortality rates comparable to the general population. These patients had tumors or 10 millimeters or less and low-grade disease (grade 1 ductal carcinoma, or grade 1 or 2 invasive lobular carcinoma.) The researchers concluded that these patients might not benefit from adjuvant therapy.

In an accompanying editorial, Jennifer J. Griggs, M.D., M.P.H., and Daniel F. Hayes, M.D., of the University of Michigan, write that the study confirms findings from other studies showing that local therapy alone is adequate for treating older women with small tumors and that "adjuvant endocrine therapy does not reduce the risk of mortality in patients with very small, node-negative hormone receptor-positive breast cancer because the risk of mortality is already extremely low."

However, the editorialists add that overall adjuvant therapy is effective in reducing the risk of recurrence in the same or opposite breast and that many women will continue to take it for that reason. "Clearly, patient preferences regarding risks and benefits of endocrine therapy play a critical role in decision making, and high-quality information support is essential in these settings."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Peer Christiansen, Karsten Bjerre, Bent Ejlertsen, Maj-Britt Jensen, Birgitte B. Rasmussen, Anne-Vibeke Lζnkholm, Niels Kroman, Marianne Ewertz, Birgitte Offersen, Dorte B. Toftdahl, Susanne Mψller, Henning T. Mouridsen, and on behalf of the Danish Breast Cancer Cooperative Group. Mortality Rates Among Early-Stage Hormone Receptor–Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark. J Natl Cancer Inst, August 31, 2011 DOI: 10.1093/jnci/djr299

Cite This Page:

Journal of the National Cancer Institute. "Adjuvant therapy perhaps not necessary for older breast cancer patients, study suggests." ScienceDaily. ScienceDaily, 31 August 2011. <www.sciencedaily.com/releases/2011/08/110831205951.htm>.
Journal of the National Cancer Institute. (2011, August 31). Adjuvant therapy perhaps not necessary for older breast cancer patients, study suggests. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/08/110831205951.htm
Journal of the National Cancer Institute. "Adjuvant therapy perhaps not necessary for older breast cancer patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/08/110831205951.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) — America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) — A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins